Open AccessPredicting Hemolytic Uremic Syndrome and Renal Replacement Therapy in Shiga Toxin–producing Escherichia coli–infected Children
Author(s) -
Ryan S McKee,
David Schnadower,
Phillip I. Tarr,
Jianling Xie,
Yaron Finkelstein,
Neil Desai,
Roni D. Lane,
Kelly R. Bergmann,
Ron L. Kaplan,
Selena Hariharan,
Andrea T. Cruz,
Daniel M. Cohen,
Andrew Dixon,
Sriram Ramgopal,
Annie Rominger,
Elizabeth C. Powell,
Jennifer Kilgar,
Kenneth A. Michelson,
Darcy Beer,
Martin Bitzan,
Christopher M. Pruitt,
Kenneth Yen,
Garth Meckler,
Amy C. Plint,
Stuart Bradin,
Thomas J. Abramo,
Serge Gouin,
April J. Kam,
Abigail Schuh,
Fran Balamuth,
Tracy E. Hunley,
John T. Kanegaye,
Nicholas E. Jones,
Usha Avva,
Robert Porter,
Daniel M. Fein,
Jeffrey P. Louie,
Stephen B. Freedman
Publication year - 2019
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciz432
Subject(s) - medicine , renal replacement therapy , odds ratio , diarrhea , gastroenterology , confidence interval , hemodialysis , creatinine , pediatrics
Shiga toxin-producing Escherichia coli (STEC) infections are leading causes of pediatric acute renal failure. Identifying hemolytic uremic syndrome (HUS) risk factors is needed to guide care.